Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xcellerated T Cells in Relapsed or Refractory Indolent NHL
NCT00081783Phase 2Unknown
- Sponsor
- Xcyte Therapies
- Start
- Mar 2004
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Xcellerated T Cells in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Xcyte Therapies. Primary endpoint: Efficacy of Xcellerated T Cells. Status: unknown.
02
Drugs
Xcellerated T Cells
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00081783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081783.